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RESEARCH ARTICLE
The methyltransferase SET9 regulates TGFB1 activation of renal
fibroblasts via interaction with SMAD3
Victoria G. Shuttleworth1, Luke Gaughan2, Lotfia Nawafa1, Caitlin A. Mooney3, Steven L. Cobb3,
Neil S. Sheerin1,* and Ian R. Logan1,*,‡
ABSTRACT
Chronic kidney disease (CKD) is a global socioeconomic problem. It is
characterised by the presence of differentiated myofibroblasts, which
cause tissue fibrosis in response to TGFB1, leading to renal failure.
Here, we define a novel interaction between the SET9 lysine
methyltransferase (also known as SETD7) and SMAD3, the principal
mediator of TGFB1 signalling in myofibroblasts. We show that SET9-
deficient fibroblasts exhibit globally altered gene expression profiles in
response to TGFB1, whilst overexpression of SET9 enhances SMAD3
transcriptional activity. We also show that SET9 facilitates nuclear
import of SMAD3 and controls SMAD3 protein degradation via
ubiquitylation. On a cellular level, we demonstrate that SET9 is
broadly required for the effects of TGFB1 in diseased primary renal
fibroblasts; SET9 promotes fibroblast migration into wounds,
expression of extracellular matrix proteins, collagen contractility and
myofibroblast differentiation. Finally, we demonstrate that SET9 is
recruited to the α-smooth muscle actin gene in response to TGFB1,
providing a mechanism by which SET9 regulates myofibroblast
contractility and differentiation. Together with previous studies, we
make the case for SET9 inhibition in the treatment of progressive CKD.
KEYWORDS: TGFB1, Fibroblast, Transcriptional regulation, Chronic
kidney disease
INTRODUCTION
The earliest histological feature of chronic kidney disease (CKD) is
the aberrant accumulation of activated myofibroblasts, the cell type
responsible for replacement of normal kidney tissue with fibrosis
(Meran and Steadman, 2011). TGFB1 stimulates myofibroblast
migration to the site of tissue injury and is a key driver of
myofibroblast differentiation, characterised by their expression of
α-smooth muscle actin (α-SMA; also known as ACTA2) (Bottinger
and Bitzer, 2002; Massagué, 2012). Upon TGFB1 stimulation,
α-SMA is incorporated into intracellular stress fibres, conferring
contractile properties upon the myofibroblast (Hinz et al., 2001).
TGFB1 also stimulates fibrillar collagen-rich extracellular matrix
(ECM) production from the myofibroblast (Wynn and
Ramalingam, 2012; Zeisberg and Kalluri, 2013). Stress fibres
containing α-SMA indirectly transmit mechanical tension through
this ECM, maintaining myofibroblast differentiation and facilitating
tissue retraction (Tomasek et al., 2002). During normal healing after
tissue injury, these events allowwound contraction and resolution to
occur. However, in the context of CKD and other fibrotic diseases,
persistent myofibroblast activity, driven by TGFB1, results in
pathological development of fibrosis.
TGFB1 is able to signal through serine-threonine kinase
transmembrane receptors (type I and type II receptor heterodimers),
which directly phosphorylate the downstream intracellular receptor-
regulated SMADproteins (R-SMADs) SMAD2 and SMAD3 (Shi and
Massagué, 2003). R-SMAD heterocomplexes, along with SMAD4,
are then translocated to the nucleus in order to regulate transcription of
fibrotic genes such as α-SMA and collagens, by recruitment of
transcriptional co-activators (Inoue et al., 2007). This pathway can be
suppressed by ubiquitin-mediated destruction of TGFB receptors and
R-SMADs, including SMAD7 (Fukuchi et al., 2001; Kavsak et al.,
2000; Yan et al., 2016). Recent data show that SMAD ubiquitylation is
reversible (Inui et al., 2011; Nan et al., 2016). Several studies have
shown that TGFB1–SMAD3 signalling is required for renal fibrosis in
mouse models of CKD (Fujimoto et al., 2003; Inazaki et al., 2004; Liu
et al., 2012; Sato et al., 2003;Wang et al., 2007), raising the possibility
of targeting this pathway to treat CKD.
SET9 (also known as SETD7) belongs to the evolutionarily
conserved Su(var) enhancer of zeste and trithorax domain family
containing lysine methyltransferases that are important in
transcriptional regulation, and was originally shown to methylate
lysine 4 in isolated histone H3 (H3K4) (Wang et al., 2001).
Interestingly, however, SET9 only weakly methylates H3K4 in
intact nucleosomes, and cells from the SET9-knockout mouse contain
unaltered total methyl H3K4 levels (Lehnertz et al., 2011) pointing
towards functional redundancy between methyltransferases and
hinting at a role for SET9 elsewhere. SET9 was subsequently shown
to regulate various transcription factors involved in differentiation,
including p53, AR, ERα, NFκB, DNMT1,MyoD, FoxO3 and TAF10
(Calnan et al., 2012; Chuikov et al., 2004; Ea and Baltimore, 2009;
Esteve et al., 2009; Gaughan et al., 2011; Kouskouti et al., 2004;
Subramanian et al., 2008; Tao et al., 2011) and non-transcriptional
proteins (Oudhoff et al., 2016; Shan et al., 2013). Nevertheless,
because SET9 appears to be dispensable for p53 function in vivo and
SET9-deficient mice undergo normal development (Campaner et al.,
2011; Lehnertz et al., 2011) questions have again been raised over the
true role of this methyltransferase (Keating and El-Osta, 2013).
Recent work has demonstrated that SET9 is involved in TGFB1-
mediated ECM production in pulmonary fibrosis by a mechanism
involving direct lysine methylation, and ubiquitin-mediated
degradation of SMAD7 (Elkouris et al., 2016). Complementary
work has shown that SET9 regulates ECM gene expression at a
more downstream transcriptional level, through histone H3
monomethylation (Sun et al., 2010) and that SET9 inhibition may
reduce fibrosis in a mouse model of ureteric obstruction (SasakiReceived 25 June 2017; Accepted 27 November 2017
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et al., 2016). Whilst these studies define an important role for SET9
in ECM production, the role of SET9 in governing key fibroblast
activities, including myofibroblast differentiation, wound healing
and collagen contractility, remains unexplored. Additionally, the
possibility that SET9 regulates R-SMADs also remains unexplored.
Here, we demonstrate a novel interaction between SET9 and
SMAD3, the key downstream R-SMAD in the TGFB1 pathway that
is required for renal fibrosis. We show that SET9 regulates SMAD3
through multiple molecular mechanisms and influences important
TGFB1-mediated processes including collagen contractility and
α-SMA-driven differentiation of primary human kidney fibroblasts.
We propose that pharmacological inhibition of SET9 could be
important in the treatment of CKD.
RESULTS
SET9 is required for the fibroblast response to TGFB1
Given the uncertainty over SET9 function, we examined global
gene expression in Set9−/− mouse embryonic fibroblasts (MEFs)
compared with MEFs from wild-type (Set9+/+) mice. Under normal
growth conditions we observed that 760 genes were expressed at
1.5-fold or higher (range, 1.5- to 67-fold) in Set9+/+ compared with
Set9−/−MEFs (Table S2). Gene set enrichment analysis (GSEA) of
these 760 genes produced cytoskeleton, wound healing and
extracellular matrix amongst the 6 highest-ranked annotations –
processes that are known to be regulated by TGFB1 (Table 1). We
additionally treated MEFs with TGFB1 for 48 h. Under these
conditions the number of differentially expressed genes in Set9+/+
compared with Set9−/− MEFs increased to 2434 (range 1.5- to
66.53-fold, Table S3). Of the 760 genes differentially expressed
under normal growth conditions 644 genes were also found to be
differentially expressed among the 2343 genes altered upon TGFB1
treatment, demonstrating consistent effects of loss of SET9. GSEA
of the 2343 SET9-regulated genes increased gene numbers under
the previously listed annotations, in particular cytoskeleton,
ubiquitin conjugation and extracellular matrix (Table 1).
Additional data from a 24 h TGFB1 time point indicated that the
highest ranking annotations remain enriched in response to TGFB1
treatment, including extracellular matrix, ubiquitin conjugation (the
highest two ranking of all annotations at 24 h TGFB1 treatment) and
cytoskeleton (Tables S1,S4). Overall, we conclude that SET9 is
required for the fibroblast response to TGFB1.
SET9 interacts with and is a co-activator for SMAD3
We next examined whether SET9 could regulate TGFB1 signalling
through downstream signalling mechanisms. We studied SMAD3, the
principal factor that propagates TGFB1 signalling to the nucleus, in
HKC-8 cells that are known to have an intact TGFB1 pathway.
Immunoprecipitation of endogenous SET9 resulted in co-
immunoprecipitation of SMAD3, in contrast to immunoprecipitation
with control immunoglobulins (Fig. 1A). We observed enrichment of
the SMAD3–SET9 interaction upon exogenous TGFB1 treatment. In a
reciprocal experiment, immunoprecipitation of endogenous SMAD3
resulted in co-immunoprecipitation of SET9 (Fig. S1A). Even upon
adjustment of cell lysates to 600 mM sodium chloride, we could still
co-immunoprecipitate SET9 in a specific manner (Fig. S1A),
demonstrating a strong SMAD3–SET9 interaction.
To exclude the possibility that antisera cross-reactivity caused these
results, we immunoprecipitated overexpressed FLAG-tagged SET9
via the FLAG epitope. This resulted in co-immunoprecipitation of
endogenous SMAD3, again with enrichment upon TGFB1 treatment
(Fig. 1B). We next tested the SET9–SMAD3 interaction in vitro, free
of other factors such as SMAD7, which might mediate indirect
interactions. Immunoprecipitation with SMAD3 antibody led to
co-immunoprecipitation of purified recombinant full-length
SET9, only in the presence of SMAD3 (Fig. 1C). Conversely,
immunoprecipitation of purified full-length SET9 led to co-
immunoprecipitation of an N-terminal SMAD3 fragment (residues
1–211), containing the conserved MH1 domain, but not a C-terminal
SMAD3 fragment (residues 199–425) (Fig. S1B). Control
immunoglobulins did not immunoprecipitate significant quantities of
any protein. Finally, we examined whether SET9 could interact
with the transcriptionally active form of SMAD3, phosphorylated at
C-terminal serine residues 423 and 425. Immunoprecipitation with a
different SET9 antibody to that used in Fig. 1A resulted in co-
immunoprecipitation of phosphorylated SMAD3 (Fig. S1C). We
conclude for the first time that SET9 interacts directly with SMAD3, in
a manner that is enhanced by TGFB1.
Given its role in transcriptional regulation, we examined the effects
of SET9 upon SMAD3 activity, using reporter gene assays. SET9
overexpression resulted in a significant enhancement of luciferase
expression driven by a synthetic promoter containing 12 basal
SMAD3 CAGA binding sites (CAGA-luc), in a dose-dependent
fashion (Fig. 2A). Conversely, introduction of a SET9 mutant
(H297A) lacking methyltransferase activity suppressed reporter
activity, in a dominant-negative manner. We also reduced SET9
levels by means of siRNA knockdown. This resulted in a significant
reduction in CAGA-luc activity, even upon exogenous TGFB1
treatment (Fig. 2B). Finally, introduction of the characterised SET9
inhibitor R-PFI-2 also resulted in a significant reduction in CAGA-
luc activity, suggesting that SET9 methyltransferase activity is
required, at least in part, for the effects upon SMAD3 (Fig. 2C).
We also examined the effects of SET9 on a natural PAI1 cis
element driving luciferase reporter gene expression, arguably of
more physiological relevance and known to be responsive to
SMAD3. Overexpression of SET9 again significantly increased
reporter gene expression, whereas addition of SET9 siRNA reduced
reporter activity (Fig. S2). Overall, we conclude that SET9 is a
SMAD3 co-activator.
Table 1. SET9 regulates TGFB1-mediated processes
Annotation
Normal growth 10 ng/ml TGFB1
No. of genes Enrichment P No. of genes Enrichment P
Cytoskeleton 53 8.91 4.9E−8 135 27.25 3.8 E−11
Ubiquitin conjugation 73 3.7 1.6E−10 206 4.63 5.0E−29
Wound healing and angiogenesis 22 3.29 8.8E−7 38 2.32 5.1E−6
Apoptosis 32 3.23 6.3E−5 56 3.62 8.7E−6
Metal ion binding 8 2.69 1.0E−3 9 1.33 6.6E−2
Extracellular matrix 24 2.33 9.5E−7 36 4.63 8.8E−4
Set9−/− and Set9+/+ MEFs cultured under normal growth conditions or exposed to 10 ng/ml TGFB1 for 48 h were used for global gene expression analysis.
Differentially expressed gene sets between Set9−/− and Set9+/+ MEFs were used for GSEA (see Materials and Methods). The top six enriched annotations,
ranked by fold enrichment over genes returned by chance from a random gene set of identical size are listed. P-values were calculated using Fisher’s exact test.
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SMAD3 nuclear import and protein stability are dependent
upon SET9
To further understand how SET9 controls SMAD3 activity, we
examined the key regulatory steps in TGFB1 signalling: SMAD3
nuclear translocation and protein turnover. We firstly reduced SET9
levels by using siRNA, then assessed SMAD3 immunofluorescence.
Compared with cells transfected with control siRNA, in which we
observed principally nuclear staining for SMAD3,we noted amarked
redistribution of SMAD3 to the cytoplasm upon knockdown of SET9
(Fig. 3A). Additionally, subcellular fractionation demonstrated that
SMAD3 shifted from the cytoplasm in response to TGFB1, whereas
SET9 siRNA that achieved a median 75% knockdown produced a
persistent cytoplasmic pool of SMAD3 (Fig. 3B); in the absence of
Fig. 1. SET9 interacts with SMAD3. (A) HK C-8 cells were cultured for 36 h in
serum-freemedium or complete medium (CM) then treated with DMSO vehicle
(−) or 5 ng/ml TGFB1 (+) overnight. Immunoprecipitations (IPs) with either
SET9 EPR5574 or control antibody (Ctrl IgG) were followed by immunoblotting
as indicated. Representative experiments of three are shown. (B) HK C-8 cells
were transfected with FLAG-SET9 or empty control vector overnight, starved
for 24 h in serum-free medium prior to treatment with DMSO vehicle or 5 ng/ml
TGFB1 overnight. Immunoprecipitation was then performed using FLAG
antibody prior to immunoblotting as indicated. (C) Purified recombinant full-
length SET9 and SMAD3 proteins were mixed in PBS prior to
immunoprecipitation with SMAD3 Ab28379 antibody, extensive washes, then
immunoblotting as shown.
Fig. 2. SET9 is a SMAD3 co-activator. (A) HK C-8 cells transfected with
100 ng CAGA-luc and either 100 ng or 200 ng of plasmid encoding wild-type
SET9 (wt) or H297A methyltransferase-deficient SET9 (mut); n=4. Empty
vector was used to standardise total quantity of transfected DNA.
Transfectants were starved in serum-free medium for 24 h then treated
overnight with 5 ng/ml TGFB1 prior to luciferase assay. (B) HK C-8 cells
transfected for 12 h with either control (Ctrl) siRNA or those targeting SET9 or
SMAD3, then transfected the following day with CAGA-luc as above, starved in
serum-free medium for 24 h, then treated overnight with TGFB1 where
indicated, prior to luciferase assay. (C) HK C-8 cells transfected overnight with
100 ng CAGA-luc plasmid were starved in serum-free medium for 24 h
containing DMSO vehicle or R-PFI-2, where indicated. Cells were then treated
with TGFB1 overnight as shown, prior to luciferase assay. Lower panels in B
and C show western blot results. Results are mean±s.d.; all results are
representative of n=3 experiments. *P<0.05 compared with respective control
(t-test).
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exogenous TGFB1, the percentage of total SMAD3 in the nucleus
changed from 58% to 49% upon SET9 knockdown but in the
presence of exogenous TGFB1, the percentage of total SMAD3 in the
nucleus was reduced from 90% to 49% upon knockdown of SET9.
We conclude that SET9 regulates TGFB1-driven nuclear import of
SMAD3. We noted lower SMAD3 levels upon SET9 knockdown,
which we investigated further.
To understand how SET9 alters SMAD3 levels, we firstly
measured SMAD3 half-life, using cycloheximide (CHX) to block
de novo protein synthesis. We observed a SMAD3 half-life of
approximately 118 min in control cells (Fig. 3C). However, upon
SET9 knockdown therewas a lower steady state level of SMAD3, and
increased SMAD3 turnover, with a half-life of approximately 48 min,
which is less than half that of the control transfectants (Fig. 3C). No
such effect could be seen upon SMAD2 (Fig. 3C). To exclude a
confounding effect of transfection, we also examined SMAD3 half-
life in Set9−/−MEFs. Compared with wild-type MEFs, SMAD3 was
present at a similar steady state level (Fig. S3A), but exhibited a
shorter half-life in Set9−/− cells upon CHX treatment (Fig. S3B).
Finally, in order to understand whether or not SET9
methyltransferase activity was required to modulate SMAD3
turnover, we examined SMAD3 half-life in stably transfected cells
expressing either wild-type or the H297Amethyltransferase-deficient
SET9. Cells expressing wild-type SET9 demonstrated entirely stable
SMAD3 levels, whereas those expressing H297A mutant SET9
exhibited loss of SMAD3 upon CHX treatment (Fig. 3D). We could
reverse the stabilising effect of wild-type SET9 upon SMAD3 by
addition of the SET9 inhibitor R-PFI-2 (Fig. 3E). We conclude that
SET9 stabilises SMAD3 in a methyltransferase-dependent manner.
We have observed a direct interaction between SET9 and
SMAD3, and effects of SET9 upon SMAD3, whereas others have
shown that SET9 regulates SMAD7. We therefore examined the
effects of loss of SET9 upon SMAD7, in the Set9−/− MEF cells
exposed to TGFB1. Compared with Set9+/+ cells, the Set9−/− cells
exhibited markedly increased levels of SMAD7, a failure to induce
SMAD3 phosphorylation in response to exogenous TGFB1, and
lower levels of total SMAD3 protein (Fig. 3F). These data confirm
the important regulatory effect of SET9 upon SMAD7 levels
described by Elkouris et al. (2016), but also suggest that SET9
directly influences SMAD3 levels.
To explore SMAD3 turnover in more detail we examined
ubiquitylation, a process known to target SMAD3 for proteasomal
destruction. We established a nickel agarose (Ni-NTA) pull-down
assay to recover ubiquitylated SMAD3 by means of transfection of
HIS-tagged ubiquitin. Addition of the proteasomal inhibitor MG-
132 resulted in enrichment of high molecular weight SMAD3
species, characteristic of ubiquitylated SMAD3 (data not shown).
Given the effects of SET9 methyltransferase activity on SMAD3
turnover, we incorporated the SET9 inhibitor R-PFI-2 (Barsyte-
Lovejoy et al., 2014). Treatment of cells with low doses of MG-132
and R-PFI-2 resulted in an enrichment of ubiquitylated SMAD3
compared with that of cells treated with a low dose of MG-132 alone
(Fig. 4A). We also examined ubiquitylation in cells stably
expressing wild-type SET9 or methyltransferase-deficient H297A
SET9. We observed a relative enrichment in ubiquitylated SMAD3
from cells expressing the H297A mutant in comparison to cells
expressing wild-type SET9 (Fig. 4B). We conclude that SET9
methyltransferase activity is involved in regulating SMAD3
stability, in a manner that influences SMAD3 ubiquitylation and
proteasomal destruction.
To test whether or not SET9 can directly methylate SMAD3, we
used both recombinant full-length SMAD3 and a series of SMAD3
Fig. 3. SET9 regulates SMAD3 nuclear import and protein turnover. (A) HK
C-8 cells were transfected with either control siRNA or those targeting SET9 for
12 h, starved in serum-free medium for 24 h prior to overnight treatment with
5 ng/ml TGFB1. Fixed cells were stained with the indicated antibodies and
appropriate Alexa Fluor-labelled secondary antibodies. Control slides with
control primary antisera did not exhibit fluorescence (not shown). (B) HK C-8
cells were transfected and starved as in A then treated with vehicle (0) or TGFB1
(1–5 ng/ml) overnight. Nuclear (n) and cytoplasmic (c) fractions were subject to
immunoblotting as indicated, using HDAC1 as a nuclear marker. (C) HK C-8
cells were transfected and starved as in A then treated with TGFB1 (5 ng/ml)
overnight. 50 µg/ml cycloheximide (CHX) was then applied for the indicated
times prior to western blotting as indicated. (D) HK C-8 cells stably expressing
wild-type FLAG-SET9 or methyltransferase-deficient FLAG-H297A mutant
SET9 were treated as in C. (E) HK C-8 cells stably expressing wild-type FLAG-
SET9 were treated as in C, except that 5 µM R-PFI-2 was added at the same
time as TGFB1, prior to cycloheximide (CHX) application for the indicated times.
(F) Set9+/+ or Set9−/− MEFs were treated with 5 ng/ml TGFB1 for the indicated
time points, prior to immunoblotting with the indicated antibodies. All results are
representative of n=3 experiments (except for B, where n=2).
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synthetic peptides as substrates for in vitro radioisotope-based
methylation assays. Whilst we could readily detect methylation of
histones by SET9, we failed to demonstrate methylation of either
full-length SMAD3 or SMAD3 peptides. Additionally, we failed to
detect methylation of the synthetic SMAD3 peptides by mass
spectrometry (data not shown).
SET9 is involved in wound healing, contractility and ECM
production in diseased renal fibroblasts
We evaluated the biological significance of SET9 in fibroblasts,
which are known to be dependent upon TGFB1 and SMAD3 for
differentiation to myofibroblasts (Evans et al., 2003).We again utilised
MEFs, but also diseased human primary renal (myo)fibroblasts (PRFs)
from fibrotic kidneys (three patients) and human mesangial cells.
Whereas PRFs are responsible for tubulointerstitial fibrosis, mesangial
cells cause glomerulosclerosis, the two entities constituting renal
fibrosis in CKD.
Firstly, we examined fibroblast morphology. Whilst normal
MEFs adopt a spindle-shaped appearance in response to TGFB1, in
keeping with myofibroblast differentiation, Set9−/− MEFs failed to
undergo this characteristic change (Fig. 5A), a phenotype also
shared with Smad3−/− MEFs. Next, we examined fibroblast
migration in wound healing assays in response to TGFB1, as a
model of fibroblast recruitment in tissue injury. Whilst normal
MEFs were capable of migrating to allow wound closure, Set9−/−
MEFs were unable to do so (Fig. 5B), which is another property
shared by Smad3−/−MEFs. Addition of the SET9 inhibitor R-PFI-2
to PRFs also significantly retarded thewound healing assay (Fig. 5C
and Fig. S4A). This effect was reproducible in PRFs from all three
patients (Fig. S4A). Normal MEFs and mesangial cells also
exhibited equally poor wound closure upon R-PFI-2 treatment
(data not shown). In the absence of TGFB1, R-PFI-2 had minimal
effect on wound closure (Fig. S4B). We conclude for the first time
that SET9 is important in fibroblast migration into the wound in
response to TGFB1 – a key process in fibrosis.
We next assessed the role of SET9 in collagen contractility,
an established methodology for studying myofibroblast–ECM
interactions, and a model of tissue retraction in fibrosis (Grinnell,
2000). Compared with wild-type MEFs, Set9−/− MEFs exhibited
significantly reduced collagen contractility (Fig. 6A), which was
Fig. 4. SET9 regulates SMAD3 ubiquitylation. (A) HK C-8 cells were
transfected with His-tagged ubiquitin (His-Ub) and either empty vector or
FLAG-SMAD3 prior to treatment with 5 ng/ml TGFB1 for 24 h. Either DMSO
vehicle or R-PFI-2 was then applied overnight along with 1 µMMG-132 prior to
Ni-NTA pulldowns then immunoblotting. All cells received MG-132 and
TGFB1. Ubiquitylated SMAD3 species are indicated (Ub-SMAD3). (B) HK C-8
cells stably expressing wild-type FLAG-SET9 (wt) or methyltransferase-
deficient FLAG-H297A (mt) were transfected and treated with TGFB1 andMG-
132 as in A, then subjected to Ni-NTA pulldowns and immunoblotting as
indicated. Ubiquitylated SMAD3 species detected with SMAD3 antibody are
indicated (Ub-SMAD3). All results are representative of n=3 experiments.
Fig. 5. SET9 regulates TGFB1-driven transformation and wound healing.
(A) MEFs with the indicated genotypes were starved in 0.5% serum-containing
medium for 36 h, then subject to overnight treatment with 5 ng/ml TGFB1
prior to light microscopy. (B) MEFs with the indicated genotypes were grown in
cell culture inserts, in quadruplicate, overnight with 5 ng/ml TGFB1 or vehicle
prior to wound formation by chamber removal. Wounds were photographed
every 4 h, then surface coverage was calculated. (C) PRFs were treated
as in B, except cells were simultaneously treated with either DMSO vehicle or
5 µM R-PFI-2 alongside 5 ng/ml TGFB1. Representative data from one patient
of three are shown. Values are mean±s.d.
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phenotypically similar to Smad3−/− cells. This could be observed
by measuring either collagen disc diameter or weight (Fig. 6A and
data not shown). Addition of R-PFI-2 to PRFs from the three
patients also showed a marked and reproducible reduction in
collagen contractility (Fig. 6B). Application of R-PFI-2 to human
mesangial cells or normal MEFs also resulted in a significant
reduction in contractility (data not shown). In the absence of
TGFB1, R-PFI-2 had minimal effect on collagen contractility
(Fig. S4C). We infer that SET9 is required for fibroblast-mediated
collagen contractility in response to TGFB1.
Next, we investigated the expression of ECM proteins. Previous
studies have suggested that SET9 contributes to ECM production in
lung fibrosis and mesangial cells (see Introduction) and collagens I
and III are known to be key in fibrotic replacement of normal
parenchyma. We observed significantly lower expression of
collagens I and III and fibronectin-1 in Set9−/− MEFs versus
wild-type MEFs in the presence of TGFB1 (Fig. 6C and Fig. S5A
for example images). Importantly, treatment with R-PFI-2
significantly decreased the expression of ECM proteins in the
diseased PRFs (Fig. 6C and Fig. S5B for example images). We
deduce that SET9 is required for PRF expression of ECM in
response to TGFB1, in keeping with previous reports (Elkouris
et al., 2016; Sun et al., 2010).
SET9 regulates α-SMA expression and is recruited to the
α-SMA gene promoter
Having shown altered myofibroblast contractility upon SET9
inhibition, we finally examined α-SMA, the most widely accepted
marker of TGFB1-induced myofibroblast differentiation and
contractility, but not previously known to be regulated by SET9.
We established a chromatin immunoprecipitation assay to examine
recruitment to the SMAD3 binding site within the α-SMA gene.
Firstly, we observed a 2.6-fold enrichment of SMAD3, and a 3.8-
fold enrichment of SET9, to the α-SMA gene but not the GAPDH
gene, in response to TGFB1 in PRFs (Fig. 7A and Fig. S6A). These
are the first data describing regulation of α-SMA by SET9. We then
examined SET9 knockdown; we observed an ∼80% reduction in
SMAD3 recruitment upon transfection of SET9 siRNA or SMAD3
siRNA (Fig. 7B and Fig. S6B). In keeping with a role for SET9 in
SMAD3 protein turnover, the addition of MG-132 partly reversed
the effect of SET9 knockdown on SMAD3 recruitment to the
α-SMA gene. We went on to observe a ∼60% reduction in α-SMA
Fig. 6. SET9 regulates TGFB1-driven collagen
contractility and fibrotic gene expression. (A) MEFs with
the indicated genotypes were used in collagen contractility
assays in triplicate, after treatment with 5 ng/ml TGFB1.
Images show single representative collagen discs overlying
ruler measure. (B) PRFs were treated as in A, except cells
were simultaneously treated with either DMSO vehicle or
5 µMR-PFI-2 along with 5 ng/ml TGFB1. (C) MEFs with the
indicated genotypes were seeded into glass chamber
slides, starved in 0.5% serum-containing medium then
treated with 5 ng/ml TGFB1 for 72 h prior to indirect
immunofluorescence with the indicated antibodies. Four
random images per slide were captured and ImageJ
software used to determine relative levels of fluorescence.
(D) PRFs from diseased kidneys were treated as in (C)
except cells were treated with 5 ng/ml TGFB1 and either
vehicle or 5 µM R-PFI-2 for 72 h prior to
immunofluorescence. All results are representative of n=3
experiments; values are mean±s.d. All changes in C and D
demonstrate statistical significance, P<0.05 (t-test).
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expression at the protein level in PRFs from all three patients in the
presence of R-PFI-2, suggesting that SET9 inhibition prevents these
cells from undergoing myofibroblast differentiation in response to
TGFB1 (Fig. 7C). We also noted that addition of R-PFI-2 also
reduced basal levels of α-SMA expression, which are likely to be
stimulated by endogenous TGFB1 production. We conclude that
SET9 is key to PRF differentiation and contractility in response to
TGFB1.
DISCUSSION
Here, we show that SET9 interacts with SMAD3 and increases
SMAD3 transcriptional activity, protein turnover and nuclear
import. These are the first data showing this direct interaction and
its effects on TGFB1 signalling.
Prior work has shown that the upstream regulatory protein
SMAD7 is a target for SET9methylation, resulting in its destruction
through Arkadia-mediated ubiquitylation (Elkouris et al., 2016).
SMAD3 protein levels, localization and transcriptional activity were
not examined in that study. We confirm here that loss of SET9
stabilises SMAD7 in MEF cells. Interestingly, SMAD7 has recently
been shown to interact with the conservedMH2 domain of SMAD3,
resulting in SMAD3 destruction (Yan et al., 2016). Given that SET9
methylates SMAD7, it is possible that some of the effects of SET9
that we describe here are mediated, in part, through this indirect
mechanism. For example, the stabilization of SMAD3 by SET9 we
observed was dependent upon SET9 methyltransferase activity,
but we could not demonstrate methylation of SMAD3 by SET9.
This effect might therefore be indirectly mediated by SMAD7
methylation.
Nevertheless, we show that SET9 can interact directly with
SMAD3 in the absence of SMAD7, and that SET9 interacts with the
SMAD3 N-terminal MH1 domain, whereas SMAD7 was shown to
interact with the C-terminal MH2 domain of SMAD3 (Yan et al.,
2016). In keeping with SET9 having direct regulatory effects upon
SMAD3, treatment of cells with the SET9 inhibitor R-PFI-2 or
transfection of methyltransferase-deficient SET9 did not inhibit
SMAD3 nuclear import (data not shown). If this effect was SMAD7
dependent, we predict that SET9 methyltransferase activity would
be required. Additionally, the very low levels of total SMAD3
protein observed in Set9−/− cells suggest that SET9 has a direct
influence on SMAD3 stability. We suggest that the different
regulatory mechanisms upon SMADs –methylation and destruction
in the case of SMAD7 but stabilization, nuclear import and
transcriptional activation in the case of SMAD3 – makes SET9 a
unique regulatory component of TGFB1 signalling. It is currently
unclear whether SET9 interacts with other SMAD proteins aside
from SMAD3 and SMAD7; however, we failed to identify an
interaction between SMAD2 and SET9 by co-immunoprecipitation
using antibodies against SMAD2 (data not shown).
Fibrosis is driven by TGFB1, which stimulates myofibroblast
activities (Duffield, 2014). Whilst the origin of fibroblasts is
debated, it is accepted that histologically confirmed fibrosis predicts
poorer clinical outcomes in CKD (Menn-Josephy et al., 2016).
There are no specific treatments to retard fibrosis (Tampe and
Zeisberg, 2014). Previous work has shown that SET9 is important in
ECM production in fibrosis (Elkouris et al., 2016; Sasaki et al.,
2016) but the role of SET9 in other fibrotic processes is unclear. We
demonstrate for the first time that SET9 is recruited to the α-SMA
gene and that SET9 is required for SMAD3 occupancy at the
α-SMA gene in PRFs, in response to TGFB1. These events
coincide with TGFB1-mediated differentiation through expression
of α-SMA, and increased collagen contractility. Taken together, our
Fig. 7. SET9 regulates TGFB1-driven α-
SMA expression. (A) PRFs were treated
with either vehicle or 5 ng/ml TGFB1 for
24 h prior to chromatin immunoprecipitation
with either SMAD3 Ab28379 (left) or SET9
C24B1 (right) antibodies. Control
immunoglobulins (IgG ctrl) were included to
show specificity. ChIP material was subject
to PCR for either α-SMA or GAPDH to
demonstrate selective recruitment. Purified
human genomic DNA was used as a
positive control in PCR (PCRcontrol); NTC,
no template control reaction. (B) PRFswere
transfected with siRNA targeting either
SET9, SMAD3 or control siRNA (Ctrl
siRNA). 24 h later, all cells were treated
with 5 ng/ml TGFB1 and 5 µM MG-132
where indicated. A further 24 h later, cells
were used in chromatin
immunoprecipitation assays with SMAD3
Ab28379, as described in A. (C) PRFs were
treated simultaneously with either DMSO
vehicle or 5 µM R-PFI-2 along with 5 ng/ml
TGFB1 as in B and immunostained to
detect α-SMA; nuclei are stained blue with
DAPI. All results are representative of n=3
experiments; values are mean±s.d.
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data are consistent with a model in which SET9 mediates SMAD3
stabilization, nuclear import and subsequent recruitment to
upregulate the α-SMA gene. Myofibroblast differentiation,
α-SMA expression and collagen contractility are key features of
fibrosis. Our results therefore suggest that SET9 inhibition might
retard these myofibroblast activities in order to treat CKD (Duscher
et al., 2014; Liu et al., 2003).
We additionally show for the first time that migration, which
accounts for the presence of myofibroblast accumulation at the site
of injury (Bochaton-Piallat et al., 2016), and perpetuation of fibrosis
elsewhere within the organ, is dependent upon SET9. Previous
work has shown that SET9 promotes ECM deposition in fibrosis;
we also show that SET9 is required for ECM protein production,
specifically in PRFs. Taken together, we propose that inhibition of
myofibroblast accumulation at the site of injury, through targeting
SET9, should reduce subsequent ECM deposition, as an additional
means to treat CKD.
One limitation of our study is that it is currently unclear whether
changes in gene expression, resulting from SET9 acting as a SMAD3
co-activator, account for all the phenotypic effects we observe in PRF
cells. It is possible that some of the non-genomic effects of SET9
upon TGFB1–SMAD3 signalling we have observed might be
responsible for the phenotypic effects of SET9 observed in
myofibroblasts. We have not examined what proportion of genes
altered in Set9−/− MEF cells in response to TGFB1 are co-regulated
by SMAD3. It is possible that some of the gene expression changes
we observe at the 48 h TGFB1 time point could result from activation
of factors additional to SMAD3.Nevertheless, the stark differences in
gene expression observed between the wild-type versus Set9−/−MEF
cells, supports our original conclusion that SET9 is required for the
global TGFB1 response, whether that is mediated solely through
SMAD3 or via SMAD3 plus additional factors.
Recent data has suggested that loss of TGFB2 receptors does not
prevent renal fibrosis in mouse models of CKD and that targeting
upstream TGFB1 signalling in kidney disease may not be effective
(Voelker et al., 2016). Nevertheless, SMAD3-deficient mice are
resistant to renal fibrosis. Additionally, SMAD3 can be activated in
a manner that is independent of TGFB1 to cause fibrosis (Chung
et al., 2010; Li et al., 2004). It therefore remains likely that
downstream signalling molecules such as SMAD3 and SET9
remain valid targets in CKD and other fibrotic diseases.
MATERIALS AND METHODS
Microarray and gene ontology
Set9+/+ and Set9−/− MEFs were cultured in the presence or absence of
TGFB1 before two-step total RNA extraction using Trizol and PureLink
Micro scale columns (Life Technologies). RNA quality and cRNA synthesis
was assessed and performed at The Wellcome Trust Centre for Human
Genetics, as was cRNA hybridisation to Illumina Mouse WG-6 arrays.
Quality control checks and normalisation was performed as described
(Jones et al., 2015), again at that facility. Gene sets showing 1.5-fold or more
upregulation between wild-type and Set9−/− MEFs were used for GSEA
with the functional annotation tool of the DAVID Bioinformatics Resource
v.6.8, default settings (Huang da et al., 2009a; Huang da et al., 2009b). The
top six enriched annotations, ranked by fold enrichment over genes returned
by chance from a random gene set of identical size are listed. Microarray
data, including the full data gene sets can be found in Tables S2–S4.
Immunoprecipitation (IP), protein purification, antibodies
For IP, cells were lysed in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100 with cOmplete protease inhibitors (Roche).
Antibodies against SMAD3 (Abcam, Ab28379), SET9 (Millipore,
EPR5574 or Cell Signaling Technology C24B1), FLAG (Sigma, F3165)
or isotype control were crosslinked to Protein A Dynabeads using BS3
(Fisher). Where stated, lysates were adjusted to the required concentration of
NaCl prior to immunoprecipitation with crosslinked antibodies overnight.
For immunoblotting, SET9 rabbit monoclonal was used throughout (Cell
Signaling Technologies, C24B1, 1:1000 dilution) and Veriblot secondary
antibodies (Abcam, Ab131366, 1:1000 dilution) were used to avoid obscuring
immunoglobulin chains. The two SMAD3 antibodies used, used at 1:1000
dilution, Ab28379 and phospho-SMAD3 423/425 (Cell Signaling
Technology, C25A9) do not cross-react with other SMAD family members.
Full-length recombinant SMAD3 (50991-M20B) and SET9 (14-469) were
purchased from Sino Biologicals and Millipore, respectively. GST-tagged
SMAD3 fragments were expressed from pGEX plasmids (Addgene)
transformed into BL21 E. coli (Zhang et al., 1998) and purified over GST
SpinTrap columns (GE Healthcare). Equimolar concentrations of recombinant
proteins were mixed in PBS for 2 h prior to immunoprecipitation with the
indicated antibodies, followed by extensive washing in PBS containing 0.05%
Tween-20 and were then used for immunoblotting.
Fibroblast isolation, immunofluorescence, transfections,
reporter assays and protein half-life analysis
Diseased renal fibroblasts from three patients were used in each assay
described (DV Biologics). They were characterised by positive expression
of vimentin, α-SMA, collagen I and III, electron microscopy and lack of
tubular cell markers (not shown). For immunofluorescence, cells were
seeded into glass chamber slides, treated as indicated, fixed with methanol
and stained using antibodies listed (1:100 dilution). Fluorescence from
Alexa Fluor-conjugated secondary antibodies (1:1000 dilution) was
captured using a Zeiss Axioimager fluorescence microscope across four
separate fields. Fluorescence in each field was then divided by the number of
cells present (indicated by DAPI staining) to determine fluorescence per
cell. Mean fluorescence across the four fields was then calculated and
expressed as percentage of the highest values and subject to ANOVA
statistical analysis. For western blot densitometry, ImageJ was used to
subtract background signal from the band of interest prior to correction for
signal arising from the relevant loading control.
Cells were transfected using Lipofectamine or RNAiMAX (Life
Technologies) for plasmids or siRNA (30 nM), respectively. siRNA
sequences have been described previously (Chuikov et al., 2004;
Gaughan et al., 2011). Reporter assays were performed as described
(Logan et al., 2009). Nuclear and cytoplasmic fractions were prepared using
IGEPALCA-630 (Sigma). For protein half-life assessment, cells transfected
with siRNA or the indicated plasmids were treated with 50 µg/ml
cycloheximide (Sigma) or DMSO vehicle for the indicated times prior to
direct lysis into Laemmli buffer then immunoblotting. R-PFI-2 (Sigma) was
used at the concentrations indicated.
Ubiquitylation, wound healing and collagen contractility
analysis
To examine ubiquitylation, cells were transfected overnight with the
indicated plasmids, treated with 10 ng/ml TGFB1 and low-dose 1 µM MG-
132 then used for Ni-NTA chromatography as described (Logan et al.,
2016). Wound healing assays were performed using two-chamber cell
culture inserts (Ibidi). After allowing cells to adhere, they were treated as
indicated then chambers removed and serial imaging performed to monitor
wound closure, as stipulated by the manufacturer. For collagen contractility
assays, 50,000 cells per sample were suspended into 0.5 ml of 0.65 mg/ml
collagen I (BD Biosciences) in DMEM with 3.7 mM NaOH, per well of a
24-well plate then allowed to set for 30 min; 0.5 ml DMEM was then
overlaid and matrices allowed to stress for 48 h. Matrices were then released
from thewell with a needle and serial diameter measurements taken. Sample
weight was measured at the assay end point.
Chromatin immunoprecipitation
Chromatin from PRFs was prepared, after cross-linking cells in 1%
formaldehyde for 10 min at room temperature, using ChromaFlash High-
Sensitivity ChIP Kit (Epigentek); 20 µg chromatin was used, with 1 µg of
the respective antibody. Oligonucleotide sequences 5′-TTTCAGCTTCC-
CTGAACACC-3′ and 5′-CGGGTAATTAAAAGAGCCACTG-3′ were
used to amplify the human sequence corresponding to the Rat SBE2
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SMAD binding element, identified by sequence alignment (Hu et al., 2003),
with 19 cycles of conventional PCR or SYBR green-based quantitative real-
time PCR with ROX reference dye, incorporating melt curve analysis
(Sigma S4438). GAPDH oligonucleotides were used as recommended in
the ChIP kit.
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Shi, Y. and Massagué, J. (2003). Mechanisms of TGF-beta signaling from cell
membrane to the nucleus. Cell 113, 685-700.
Subramanian, K., Jia, D., Kapoor-Vazirani, P., Powell, D. R., Collins, R. E.,
Sharma, D., Peng, J., Cheng, X. and Vertino, P. M. (2008). Regulation of
estrogen receptor alpha by the SET7 lysine methyltransferase. Mol. Cell 30,
336-347.
Sun, G., Reddy, M. A., Yuan, H., Lanting, L., Kato, M. and Natarajan, R. (2010).
Epigenetic histone methylation modulates fibrotic gene expression. J. Am. Soc.
Nephrol. 21, 2069-2080.
Tampe, D. and Zeisberg, M. (2014). Potential approaches to reverse or repair renal
fibrosis. Nat. Rev. Nephrol. 10, 226-237.
Tao, Y., Neppl, R. L., Huang, Z.-P., Chen, J., Tang, R.-H., Cao, R., Zhang, Y., Jin,
S.-W. and Wang, D.-Z. (2011). The histone methyltransferase Set7/9 promotes
myoblast differentiation and myofibril assembly. J. Cell Biol. 194, 551-565.
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. and Brown, R. A. (2002).
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat.
Rev. Mol. Cell Biol. 3, 349-363.
Voelker, J., Berg, P. H., Sheetz, M., Duffin, K., Shen, T., Moser, B., Greene, T.,
Blumenthal, S. S., Rychlik, I., Yagil, Y. et al. (2016). Anti-TGF-beta1 antibody
therapy in patients with diabetic nephropathy. J. Am. Soc. Nephrol. 28, 953-962.
Wang, H., Cao, R., Xia, L., Erdjument-Bromage, H., Borchers, C., Tempst, P. and
Zhang, Y. (2001). Purification and functional characterization of a histone H3-
lysine 4-specific methyltransferase. Mol. Cell 8, 1207-1217.
Wang, A., Ziyadeh, F. N., Lee, E. Y., Pyagay, P. E., Sung, S. H., Sheardown, S. A.,
Laping, N. J. and Chen, S. (2007). Interference with TGF-beta signaling by
Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting
albuminuria. Am. J. Physiol. Renal. Physiol. 293, F1657-F1665.
Wynn, T. A. and Ramalingam, T. R. (2012). Mechanisms of fibrosis: therapeutic
translation for fibrotic disease. Nat. Med. 18, 1028-1040.
Yan, X., Liao, H., Cheng, M., Shi, X., Lin, X., Feng, X.-H. and Chen, Y.-G. (2016).
Smad7 protein Interacts with receptor-regulated Smads (R-Smads) to inhibit
transforming growth factor-beta (TGF-beta)/smad signaling. J. Biol. Chem. 291,
382-392.
Zeisberg, M. and Kalluri, R. (2013). Cellular mechanisms of tissue
fibrosis. 1. Common and organ-specific mechanisms associated with tissue
fibrosis. Am. J. Physiol. Cell Physiol. 304, C216-C225.
Zhang, Y., Feng, X.-H. and Derynck, R. (1998). Smad3 and Smad4 cooperate with
c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 394, 909-913.
10
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs207761. doi:10.1242/jcs.207761
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
